Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06689904 · ClinicalTrials.gov registry record · NA
The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter
A NA study of Medication Delivery and Eye Drop Delivery, sponsored by Sutter Health.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT06689904: Completed NA study of Medication Delivery and Eye Drop Delivery, sponsored by Sutter Health.
NCT06689904 is a NA study of Medication Delivery and Eye Drop Delivery that has completed, run by Sutter Health. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06689904, a NA study of Medication Delivery and Eye Drop Delivery, has completed, sponsored by Sutter Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The average drop size produced by standard eyedrop bottle exceeds the maximal capacity that the human eye are absorb topically. This excess leads to medication waste, increased costs, and greater risk of side effects. The Nanodropper is a commercially available, FDA listed eyedrop bottle adapter that delivers a smaller drop size. The investigators hypothesize the Nanodropper is noninferior to the standard eye drop bottle for pupil dilation. In this study, participants have one eye randomly chosen to be dilated with the Nanodropper and the fellow eye dilated with the standard bottle with a 50/50 mixture of tropicamide 1% and phenylephrine 2.5%. Pupil size before and after 30 minutes of dilation are measured with a pupillometer and compared between fellow eyes to see if there is a difference.
Primary Outcome
Pupil diameter (mm)
Conditions Studied
Interventions
- DEVICE Nanodropper
- DEVICE Standard eye drop bottle
Study Locations (1)
California
- Lions Eye Clinic - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2022-01-31 |
| Phase | NA |
What the finished NCT06689904 record still lists
NCT06689904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Medication Delivery appearing as the primary indexed condition, and to 2 interventions - of which Nanodropper is the first listed.
NCT06689904 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06689904 about?
NCT06689904 is a clinical study titled "The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter". The average drop size produced by standard eyedrop bottle exceeds the maximal capacity that the human eye are absorb topically. This excess leads to medication waste, increased costs, and greater risk of side effects. The Nanodropper is a commercially available, FDA listed eyedrop bottle adapter th...
What is the current status of trial NCT06689904?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2022-01-04. Estimated completion is 2022-01-31.
What conditions does trial NCT06689904 study?
This clinical trial studies the following conditions: Medication Delivery, Eye Drop Delivery.
What interventions are being tested in trial NCT06689904?
The interventions under investigation include: Nanodropper (DEVICE), Standard eye drop bottle (DEVICE).
Who is sponsoring clinical trial NCT06689904?
This trial is sponsored by Sutter Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06689904 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06689904's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI